Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. ANIP | 0.00 |
Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:
ANIP) with a Hold rating and announces Price Target of $91.
